Drugs / MOv19-BBz CAR T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07116057 | Oct 2025 → Oct 2040 expected | non-small cell lung carcinoma | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 1 | NCT03585764 | Oct 2018 → Mar 2024 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | University of Pennsylvania | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOv19-BBz CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03585764 ↗ |
| Modality | Cell therapy | “MOv19-BBz CAR T cells” NCT03585764 ↗ |